ConductScience.org, home

Paper2993535

High-dose cisplatin in hypertonic saline in refractory ovarian cancer.

Ozols RF and 3 others. J Clin Oncol, 1985. Cited by 240 papers, by iCite.

Cite this record

ConductScience Library. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. Papers, record 2993535. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2993535

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
High-dose cisplatin in hypertonic saline in refractory ovarian cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
1985
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
240
iCite
Relative citation ratio, by iCite
10.2
iCite
Revised in PubMed
2017-02-10
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ozols RFR F
2Ostchega YY
3Myers CEC E
4Young RCR C

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CisplatinMajor topic
Ovarian NeoplasmsMajor topic
Adult
Aged
Bone Marrow
Drug Evaluation
Female
Humans
Kidney Function Tests
Middle Aged
Nausea
Peripheral Nervous System Diseases
Saline Solution, Hypertonic
Vomiting

Source PubMed

Download CSV of topics

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 240 citations.

PMIDTitleJournalYearIn PapersSource
37530985Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR.Cancer Causes Control2024https://conductscience.org/library/papers/37530985PubMed
23788859Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.Contemp Oncol (Pozn)2012https://conductscience.org/library/papers/23788859PubMed
22045362Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.J Natl Cancer Inst2011https://conductscience.org/library/papers/22045362PubMed
19916578Cisplatin overdose: toxicities and management.Drug Saf2009https://conductscience.org/library/papers/19916578PubMed
10864227Clinical pharmacokinetics and administration of established platinum drugs.Drugs2000https://conductscience.org/library/papers/10864227PubMed
9637718Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.J Clin Invest1998https://conductscience.org/library/papers/9637718PubMed
8398709Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.Br J Cancer1993https://conductscience.org/library/papers/8398709PubMed
8353050EPIC: an effective low toxicity regimen for relapsing lymphoma.Br J Cancer1993https://conductscience.org/library/papers/8353050PubMed
8261575Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8261575PubMed
8258189Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8258189PubMed
7981487New platinum agents. A comparison in ovarian cancer.Drugs Aging1994https://conductscience.org/library/papers/7981487PubMed
7850928Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7850928PubMed
7693428New cisplatin analogues in development. A review.Drugs1993https://conductscience.org/library/papers/7693428PubMed
7692922Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.Br J Cancer1993https://conductscience.org/library/papers/7692922PubMed
7497577Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7497577PubMed
3568273High-dose cisplatin in advanced head and neck cancer.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3568273PubMed
3342465Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3342465PubMed
3064798A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer.Br J Cancer1988https://conductscience.org/library/papers/3064798PubMed
3049431Evolution of high-dose cisplatin.Invest New Drugs1988https://conductscience.org/library/papers/3049431PubMed
3048763Resistance to cisplatin and analogues: mechanisms and potential clinical implications.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3048763PubMed

See all 34 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2993535

GET https://conductscience.org/api/papers/v1/2993535/cited_by?page=2